{"id":178864,"date":"2026-02-02T03:41:07","date_gmt":"2026-02-02T08:41:07","guid":{"rendered":"https:\/\/alphastreet.com\/india\/?p=178864"},"modified":"2026-02-02T03:41:07","modified_gmt":"2026-02-02T08:41:07","slug":"glenmark-rallies-as-q3-margins-expand-fda-clears-u-s-facility","status":"publish","type":"post","link":"https:\/\/alphastreet.com\/india\/glenmark-rallies-as-q3-margins-expand-fda-clears-u-s-facility\/","title":{"rendered":"Glenmark Rallies as Q3 Margins Expand, FDA Clears U.S. Facility"},"content":{"rendered":"\n<p>Glenmark Pharmaceuticals Ltd. (NSE: GLENMARK) The Mumbai-based pharmaceutical company posts strong domestic and international sales as it transitions toward an innovation-driven portfolio. Operating margins expanded on disciplined execution across key therapeutic areas and the restart of U.S. manufacturing operations.<\/p>\n\n\n\n<p>The company announced its financial results for the third quarter ended December 31, 2025, reporting a 15.1% year-on-year increase in consolidated revenue to \u20b939,006 million. The company&#8217;s performance was characterized by double-digit growth in its core Indian market and a significant expansion in operating profit margins. Net profit for the period rose 15.9% to \u20b94,032 million, reflecting improved momentum in global respiratory and oncology franchises.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\">Current Market Position<\/h2>\n\n\n\n<p>Current Stock Price:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li>Approximately \u20b91,060.00.<\/li>\n<\/ul>\n\n\n\n<p>Market Capitalization:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li>Approximately \u20b9299.12 billion ($3.59 billion).<\/li>\n<\/ul>\n\n\n\n<p>Valuation:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li>The stock trades at a trailing P\/E of approximately 25.4x, reflecting investor expectations for the company&#8217;s transition toward an innovative portfolio.<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\">Key Development<\/h2>\n\n\n\n<p>A primary driver for the company&#8217;s North American outlook is the receipt of an Establishment Inspection Report (EIR) from the U.S. Food and Drug Administration (FDA) for its manufacturing facility in Monroe, North Carolina. The facility was granted a Voluntary Action Indicated (VAI) status, allowing Glenmark to restart commercial manufacturing at the site. This development follows a period of regulatory review and is expected to facilitate the advancement of the company\u2019s U.S. product pipeline, particularly in the respiratory segment.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\">Product Highlights<\/h2>\n\n\n\n<p>Glenmark introduced several first-in-class therapies during the quarter. In India, the company launched NEBZMART GFB Smartules and Glenmark AIRZ FB Smartules, which represent the world\u2019s first nebulized fixed-dose triple therapy for Chronic Obstructive Pulmonary Disease (COPD).<\/p>\n\n\n\n<p>The company&#8217;s global respiratory brand, RYALTRIS, recorded secondary sales growth of approximately 50% year-on-year and received approval in China, with a planned launch in Q1 FY27.<\/p>\n\n\n\n<p>In the oncology segment, Glenmark entered into an exclusive agreement with Hansoh Pharmaceutical for Aumolertinib, a third-generation EGFR-TKI for lung cancer treatment, covering markets including the Middle East, Africa, and Russia.<\/p>\n\n\n\n<p>Ichnos Glenmark Innovation (IGI) is advancing ISB 2001, a first-in-class trispecific antibody for multiple myeloma, currently in Phase 1 clinical trials.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\">Financial Performance<\/h2>\n\n\n\n<p>For the quarter ended December 31, 2025, Glenmark reported the following results:<\/p>\n\n\n\n<p>\u2022 Consolidated Revenue: \u20b939,006 million, up 15.1% from \u20b933,876 million in the previous year.<\/p>\n\n\n\n<p>\u2022 EBITDA: \u20b98,697 million, representing 44.9% growth year-on-year.<\/p>\n\n\n\n<p>\u2022 EBITDA Margin: 22.3%, compared to 17.7% in the corresponding quarter last year.<\/p>\n\n\n\n<p>\u2022 Profit After Tax (PAT): \u20b94,032 million, inclusive of an exceptional item of \u20b91,843 million related to new Indian labor codes.<\/p>\n\n\n\n<p>\u2022 Regional Growth: India formulations grew 22.1% to \u20b912,986 million. North America revenue rose 24.2% to \u20b99,706 million, though core business growth was 4.1% when excluding one-time out-licensing income for ISB 2001.<\/p>\n\n\n\n<p>For the nine-month period ended December 31, 2025, consolidated revenue reached \u20b9132,119 million, a 31.3% increase over the prior year. However, full-year India revenue remained down 23.7% compared to the same nine-month period in the previous fiscal year.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\">Business Outlook &amp; Strategy<\/h2>\n\n\n\n<p>Management aims to build a structurally stronger growth trajectory by focusing on innovative branded products in dermatology, respiratory, and oncology. The strategy involves scaling RYALTRIS globally and commercializing in-licensed assets like WINLEVI in Europe by Q1 FY27. The company is also prioritizing capital allocation toward its innovative pipeline through IGI, leveraging partnerships like the one established with AbbVie for the development of ISB 2001.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\">Sector &amp; Macro Context<\/h2>\n\n\n\n<p>Glenmark continues to outperform the Indian Pharmaceutical Market (IPM). According to IQVIA data, Glenmark\u2019s India formulations business grew 15.8% in the third quarter, significantly higher than the overall market growth of 10.9%. The company maintains high rankings in its core therapeutic areas, standing 2nd in Dermatology and 2nd in Respiratory in India. In Russia, the company\u2019s secondary sales growth of 15% also exceeded the broader dermatology market.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\">Bull vs. Bear Investment Thesis<\/h2>\n\n\n\n<h2 class=\"wp-block-heading\">Bull Case<\/h2>\n\n\n\n<p>\u2022 Regulatory Recovery: The restart of the Monroe facility resolves a major U.S. regulatory overhang and provides a clear path for new product launches.<\/p>\n\n\n\n<p>\u2022 Innovative Scaling: Strong global uptake of RYALTRIS and the introduction of first-in-class COPD therapies provide a differentiated competitive advantage in high-growth respiratory markets.<\/p>\n\n\n\n<p>\u2022 Monetization of R&amp;D: The $700 million upfront payment from AbbVie for ISB 2001 demonstrates the company&#8217;s ability to successfully out-license its innovative pipeline for significant capital inflows.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\">Bear Case<\/h2>\n\n\n\n<p>\u2022 Nine-Month Domestic Slump: Despite quarterly growth, India formulations revenue is down 23.7% for the nine-month period, indicating volatility in domestic performance.<\/p>\n\n\n\n<p>\u2022 Reliance on Non-Core Income: A substantial portion of the North American revenue growth was driven by out-licensing income rather than core product sales, which grew at a more modest 4.1%.<\/p>\n\n\n\n<p>\u2022 Exceptional Costs: Ongoing financial impacts from macro-regulatory changes, such as the New Labor Codes in India, continue to affect bottom-line margins.<\/p>\n\n\n\n<p><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Glenmark Pharmaceuticals Ltd. (NSE: GLENMARK) The Mumbai-based pharmaceutical company posts strong domestic and international sales as it transitions toward an innovation-driven portfolio. Operating margins expanded on disciplined execution across key therapeutic areas and the restart of U.S. manufacturing operations. The company announced its financial results for the third quarter ended December 31, 2025, reporting a [&hellip;]<\/p>\n","protected":false},"author":2382,"featured_media":125416,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"jetpack_post_was_ever_published":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[1941,392,5747],"tags":[9323,10169,9175,14492,15352,8157,15356,15353,15363,15355,15358,10089,15360,15354],"class_list":["post-178864","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-stock-analysis","category-earnings","category-healthcare-stocks","tag-drug-manufacturers-specialty-generic-3","tag-earnings","tag-earnings-call","tag-financial-results","tag-glenmark-pharmaceuticals","tag-healthcare","tag-india-formulations","tag-indian-pharma-stocks","tag-innovation-led-pharma","tag-north-america-business","tag-pharmaceutical-sector","tag-quarterly-earnings","tag-ryaltris","tag-us-fda-clearance"],"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/alphastreet.com\/india\/wp-content\/uploads\/2021\/11\/Earnings-Coverage.jpg","jetpack_likes_enabled":false,"jetpack-related-posts":[{"id":169169,"url":"https:\/\/alphastreet.com\/india\/glenmark-pharmaceuticals-ltd-q4fy25-6-rise-in-revenue-2\/","url_meta":{"origin":178864,"position":0},"title":"Glenmark Pharmaceuticals Ltd Q4FY25; 6% rise in Revenue","author":"Divyansh_Kasana","date":"July 17, 2025","format":false,"excerpt":"Glenmark Pharmaceuticals Ltd is a global research-led pharmaceutical company with presence across generics, Specialty and OTC business with operations in over 80 countries. Financial Results: Glenmark Pharmaceuticals Ltd reported Revenues for Q4FY25 of \u20b93,256.20 Crores up from \u20b93,062.96 Crore year on year, a rise of 6.31%. Total Expenses for Q4FY25\u2026","rel":"","context":"In &quot;AlphaGraphs&quot;","block_context":{"text":"AlphaGraphs","link":"https:\/\/alphastreet.com\/india\/category\/infographics\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/07\/U-11.png?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/07\/U-11.png?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/07\/U-11.png?resize=525%2C300&ssl=1 1.5x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/07\/U-11.png?resize=700%2C400&ssl=1 2x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/07\/U-11.png?resize=1050%2C600&ssl=1 3x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/07\/U-11.png?resize=1400%2C800&ssl=1 4x"},"classes":[]},{"id":142579,"url":"https:\/\/alphastreet.com\/india\/earnings-summary-of-glenmark-pharmaceuticals-limited-for-q3-fy23\/","url_meta":{"origin":178864,"position":1},"title":"Earnings Summary Of Glenmark Pharmaceuticals Limited For Q3 FY23","author":"Hardik Bhandare","date":"February 23, 2023","format":false,"excerpt":"Glenmark Pharmaceuticals Limited (NSE: GLENMARK) is a global research-driven pharmaceutical company that develops and markets innovative drugs for major therapeutic areas such as dermatology, respiratory, oncology, and diabetes. The company operates in over 80 countries and has manufacturing facilities in India, Switzerland, and Argentina. The company's revenue is primarily generated\u2026","rel":"","context":"In &quot;Earnings&quot;","block_context":{"text":"Earnings","link":"https:\/\/alphastreet.com\/india\/category\/earnings\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/02\/898c572d-b97a-4c10-acd3-c5f4d9ad88be-20.jpg?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/02\/898c572d-b97a-4c10-acd3-c5f4d9ad88be-20.jpg?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/02\/898c572d-b97a-4c10-acd3-c5f4d9ad88be-20.jpg?resize=525%2C300&ssl=1 1.5x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/02\/898c572d-b97a-4c10-acd3-c5f4d9ad88be-20.jpg?resize=700%2C400&ssl=1 2x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/02\/898c572d-b97a-4c10-acd3-c5f4d9ad88be-20.jpg?resize=1050%2C600&ssl=1 3x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/02\/898c572d-b97a-4c10-acd3-c5f4d9ad88be-20.jpg?resize=1400%2C800&ssl=1 4x"},"classes":[]},{"id":146758,"url":"https:\/\/alphastreet.com\/india\/earnings-summary-of-glenmark-pharmaceuticals-limited-for-q4-fy23\/","url_meta":{"origin":178864,"position":2},"title":"Earnings Summary Of Glenmark Pharmaceuticals Limited For Q4 FY23","author":"Hardik Bhandare","date":"May 19, 2023","format":false,"excerpt":"Glenmark Pharmaceuticals Limited is a global pharmaceutical company headquartered in Mumbai, India. Established in 1977, the company has grown to become a leading player in the pharmaceutical industry, with a presence in over 80 countries worldwide. Glenmark focuses on developing and manufacturing innovative and affordable pharmaceutical products across various therapeutic\u2026","rel":"","context":"In &quot;Earnings&quot;","block_context":{"text":"Earnings","link":"https:\/\/alphastreet.com\/india\/category\/earnings\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/05\/898c572d-b97a-4c10-acd3-c5f4d9ad88be-5-6.png?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/05\/898c572d-b97a-4c10-acd3-c5f4d9ad88be-5-6.png?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/05\/898c572d-b97a-4c10-acd3-c5f4d9ad88be-5-6.png?resize=525%2C300&ssl=1 1.5x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/05\/898c572d-b97a-4c10-acd3-c5f4d9ad88be-5-6.png?resize=700%2C400&ssl=1 2x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/05\/898c572d-b97a-4c10-acd3-c5f4d9ad88be-5-6.png?resize=1050%2C600&ssl=1 3x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/05\/898c572d-b97a-4c10-acd3-c5f4d9ad88be-5-6.png?resize=1400%2C800&ssl=1 4x"},"classes":[]},{"id":169156,"url":"https:\/\/alphastreet.com\/india\/glenmark-pharmaceuticals-ltd-q4fy25-6-rise-in-revenue\/","url_meta":{"origin":178864,"position":3},"title":"Glenmark Pharmaceuticals Ltd Q4FY25; 6% rise in Revenue","author":"Divyansh_Kasana","date":"July 16, 2025","format":false,"excerpt":"Glenmark Pharmaceuticals Ltd is a global research-led pharmaceutical company with presence across generics, Specialty and OTC business with operations in over 80 countries. Financial Results: Glenmark Pharmaceuticals Ltd reported Revenues for Q4FY25 of \u20b93,256.20 Crores up from \u20b93,062.96 Crore year on year, a rise of 6.31%. Total Expenses for Q4FY25\u2026","rel":"","context":"In &quot;AlphaGraphs&quot;","block_context":{"text":"AlphaGraphs","link":"https:\/\/alphastreet.com\/india\/category\/infographics\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/07\/Y.png?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/07\/Y.png?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/07\/Y.png?resize=525%2C300&ssl=1 1.5x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/07\/Y.png?resize=700%2C400&ssl=1 2x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/07\/Y.png?resize=1050%2C600&ssl=1 3x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/07\/Y.png?resize=1400%2C800&ssl=1 4x"},"classes":[]},{"id":178875,"url":"https:\/\/alphastreet.com\/india\/glenmark-pharmaceuticals-q3-fy26-revenue-rises-15-1-on-strong-domestic-and-north-american-growth\/","url_meta":{"origin":178864,"position":4},"title":"Glenmark Pharmaceuticals Q3 FY26 Revenue Rises 15.1% on Strong Domestic and North American Growth","author":"Staff Correspondent","date":"February 2, 2026","format":false,"excerpt":"Glenmark Pharmaceuticals Ltd. (NSE: GLENMARK) reported consolidated revenue of \u20b939,006 million for the third quarter ended December 31, 2025, a 15.1% increase over the \u20b933,876 million recorded in the previous year. Earnings before interest, taxes, depreciation, and amortization (EBITDA) reached \u20b98,697 million, representing a 44.9% year-over-year increase. The EBITDA margin\u2026","rel":"","context":"In &quot;Analysis&quot;","block_context":{"text":"Analysis","link":"https:\/\/alphastreet.com\/india\/category\/stock-analysis\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2021\/11\/Earnings-Coverage.jpg?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2021\/11\/Earnings-Coverage.jpg?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2021\/11\/Earnings-Coverage.jpg?resize=525%2C300&ssl=1 1.5x"},"classes":[]},{"id":166692,"url":"https:\/\/alphastreet.com\/india\/glenmark-pharmaceuticals-ltd-q3fy25-16-fall-in-profits\/","url_meta":{"origin":178864,"position":5},"title":"Glenmark Pharmaceuticals Ltd Q3FY25; 16% fall in Profits","author":"Divyansh_Kasana","date":"February 5, 2025","format":false,"excerpt":"Glenmark Pharmaceuticals Ltd is a global research-led pharmaceutical company with presence across generics, Specialty and OTC business with operations in over 80 countries. Financial Results: Glenmark Pharmaceuticals Ltd reported Revenues for Q3FY25 of \u20b91,926.00 Crores up from \u20b92,507.00 Crore year on year, a rise of 5.77%. Total Expenses for Q3FY25\u2026","rel":"","context":"In &quot;AlphaGraphs&quot;","block_context":{"text":"AlphaGraphs","link":"https:\/\/alphastreet.com\/india\/category\/infographics\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/02\/O-2.png?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/02\/O-2.png?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/02\/O-2.png?resize=525%2C300&ssl=1 1.5x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/02\/O-2.png?resize=700%2C400&ssl=1 2x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/02\/O-2.png?resize=1050%2C600&ssl=1 3x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/02\/O-2.png?resize=1400%2C800&ssl=1 4x"},"classes":[]}],"jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/posts\/178864","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/users\/2382"}],"replies":[{"embeddable":true,"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/comments?post=178864"}],"version-history":[{"count":1,"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/posts\/178864\/revisions"}],"predecessor-version":[{"id":178871,"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/posts\/178864\/revisions\/178871"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/media\/125416"}],"wp:attachment":[{"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/media?parent=178864"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/categories?post=178864"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/tags?post=178864"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}